Elicio Therapeutics is a clinical-stage biotechnology company specializing in the development of innovative immunotherapies to treat cancer by harnessing the natural power of lymph nodes. Founded in 2011 and headquartered in Boston, Massachusetts, Elicio focuses on engineering lymph node–targeted immunomodulators, adjuvants, and vaccines designed to amplify the immune system’s ability to fight aggressive solid tumors[1][2][3]. The company’s lead asset is ELI-002, a multivalent lymph node–targeted amphiphile (AMP) peptide vaccine in Phase II clinical trials. ELI-002 targets seven key KRAS driver mutations, which are common oncogenic mutations in several difficult-to-treat cancers. Elicio is also advancing preclinical candidates such as ELI-007, targeting mutant BRAF-driven cancers, and ELI-008, aimed at tumors expressing mutated p53 protein. These products highlight Elicio’s platform versatility with its AMP technology, which enhances delivery specifically to lymph nodes to elicit robust T cell–mediated immune responses[1]. Elicio’s multidisciplinary team combines expertise in materials science, immunology, and oncology to pioneer a new era in cancer immunotherapy. Their approach is distinct in focusing on lymph node targeting, which acts as a biological hub to maximize immune activation. This strategy positions Elicio as a dynamic innovator in immuno-oncology, aiming to improve outcomes for patients with some of the most challenging cancers, including pancreatic ductal adenocarcinoma (PDAC)[2][3]. With around 32 employees led by CEO Robert Connelly, Elicio Therapeutics is a growing force in biopharma, actively progressing clinical trials and advancing its pipeline. The company’s commitment to collaboration and scientific excellence underscores its mission to transform cancer treatment by empowering the immune system to fight back more effectively[1][2].